Breast cancer risk assessment payment model

Full Title:
PREFERRED Screening Act

Summary#

This bill would change federal law to create a payment model that pays health care providers for doing comprehensive breast cancer risk assessments and for making personalized screening and risk‑reduction plans. The main change is adding authority under title XI of the Social Security Act to set up and pay for those services. The broad goal appears to be encouraging more use of risk assessment and individualized screening plans for breast cancer.

  • Main change: Establishes a federal payment model to reimburse providers for comprehensive breast cancer risk assessments and for developing personalized screening and risk‑reduction plans.
  • Where: The bill amends title XI of the Social Security Act (the part of law that is used to create federal payment models and demonstrations).
  • Who introduced it: Senators Bill Cassidy and Lisa Murkowski.
  • Status: Read twice and referred to the Senate Finance Committee.
  • What is unclear: The published material does not specify which patients, payers, or programs (for example, Medicare, Medicaid, private insurers) the payment model would cover, or the exact services that would be reimbursed.

What it means for you#

  • Patients (people at risk for breast cancer): This could mean more doctors or clinics are paid to do full risk assessments and to write individualized screening or risk‑reduction plans. It does not say which patients would be covered or how to enroll.
  • Primary care doctors and specialists (oncologists, gynecologists, genetic counselors): The bill would likely create a way for these providers to be paid for time spent on breast cancer risk assessment and personalized planning. The specific payment amounts and billing rules are not provided.
  • Health systems and clinics: This could change how clinics document and bill for risk assessment and planning. It may require new workflows to identify eligible patients and record assessments.
  • Insurers and federal programs: The bill uses title XI authority, which is commonly used to test payment models. It is not clear whether the model would apply to Medicare, Medicaid, or be voluntary for private insurers.
  • Researchers and public health agencies: A federal payment model could lead to more data on who gets assessed and how personalized plans are used, but the bill text provided does not describe data collection or evaluation methods.

Expenses#

No publicly available information on estimated costs or savings was provided with the material supplied.

  • Possible public costs could include payments to providers for the new services and administrative costs to run the payment model.
  • Possible private costs could include additional downstream services (for example, genetic testing or added imaging) that follow from more risk assessments.
  • It is not clear whether the bill includes offsets, limits on payments, or a time limit for the model.

Proponents' View#

  • The bill appears intended to increase use of comprehensive risk assessment and to promote personalized screening and risk‑reduction plans for breast cancer.
  • Supporters may argue that paying providers for these services would encourage more patients to get formal risk evaluation rather than one‑size‑fits‑all screening.
  • This could be seen as improving prevention and tailoring care by aligning payments with time‑consuming, non‑procedural services such as counseling and planning.

Opponents' View#

  • One concern is cost: without a fiscal estimate, it is unclear how much the model would cost and whether it would increase federal spending.
  • The bill does not clearly say which programs or patients are covered, making implementation and scope uncertain.
  • It is unclear whether there is strong evidence that broad use of risk‑based screening improves outcomes enough to justify added payments and downstream testing.
  • Increased assessments could lead to more genetic testing or imaging, potentially raising follow‑up costs and burdens on patients and the health system.
  • Administrative issues could arise: providers and payers would need rules on who qualifies, what counts as a “comprehensive” assessment, documentation, and privacy protections for sensitive risk information.